These results suggest that increased expression of PD-1 may correlate with the pathogenesis of SLE, unregulated PD-1 expression may be a biomarker for SLE diagnosis, and PD-1 inhibitor may be useful for SLE treatment. This evidence concerns the gene PDCD1 and systemic lupus erythematosus.